What is the current valuation of the Cancer Biological Therapy Market?

As of 2024, the market valuation was 116.29 USD Billion. Read More

What is the projected market size for the Cancer Biological Therapy Market by 2035?

The market is projected to reach 356.19 USD Billion by 2035. Read More

What is the expected CAGR for the Cancer Biological Therapy Market during the forecast period 2025 - 2035?

The expected CAGR for the market during this period is 10.67%. Read More

Which companies are considered key players in the Cancer Biological Therapy Market?

Key players include Roche, Bristol-Myers Squibb, Amgen, Merck & Co., Novartis, Gilead Sciences, AstraZeneca, Pfizer, and Johnson & Johnson. Read More

What are the main applications of cancer biological therapies?

The main applications include Monoclonal Antibodies, Cancer Vaccines, Cytokines and Interferons, Gene Therapy, and Oncolytic Virus Therapy. Read More

How does the market for Monoclonal Antibodies compare to other segments?

The market for Monoclonal Antibodies was valued at 40.0 USD Billion in 2024 and is projected to reach 120.0 USD Billion by 2035. Read More

What types of cancer are primarily targeted by biological therapies?

Biological therapies primarily target Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, and Leukemia. Read More

What is the projected market size for Immunotherapy by 2035?

The market for Immunotherapy is expected to grow from 40.0 USD Billion in 2024 to 120.0 USD Billion by 2035. Read More

What treatment modalities are included in the Cancer Biological Therapy Market?

The treatment modalities include Targeted Therapy, Immunotherapy, Combination Therapy, Adjuvant Therapy, and Neoadjuvant Therapy. Read More

What is the expected growth trajectory for the Oncolytic Virus Therapy segment?

The Oncolytic Virus Therapy segment was valued at 16.29 USD Billion in 2024 and is projected to reach 56.19 USD Billion by 2035. Read More

Cancer Biological Therapy Market

ID: MRFR/Pharma/0173-CR

85 Pages

Rahul Gotadki

Last Updated: January 13, 2026

EMEA Cancer Biological Therapy Market information, by type (monoclonal antibodies, interferons, interleukins, cancer growth inhibitors, gene therapy, colony-stimulating factors, targeted therapy, cancer vaccines and others) by end users (hospitals & clinics, cancer research centers, laboratories) - Growth & Industry Forecast 2025 To 2035

Cancer Biological Therapy Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)10.67%

2024 Market Size$ 116.29 Billion

2025 Market Size$ 130.03 Billion

2035 Market Size$ 356.19 Billion

Key Players

Roche

Bristol-Myers Squibb

Amgen

Merck & Co.

Novartis

Gilead Sciences

Trends

Personalized Medicine
Innovative Collaborations
Regulatory and Reimbursement Dynamics

Opportunities

Rising Incidence of Cancer
Growing Awareness and Education
Regulatory Support and Approvals

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Billion)
  1. 4.1.1 Monoclonal Antibodies
  2. 4.1.2 Cancer Vaccines
  3. 4.1.3 Cytokines and Interferons
  4. 4.1.4 Gene Therapy
  5. 4.1.5 Oncolytic Virus Therapy
2. 4.2 Healthcare, BY Type of Cancer (USD Billion)
  1. 4.2.1 Breast Cancer
  2. 4.2.2 Lung Cancer
  3. 4.2.3 Colorectal Cancer
  4. 4.2.4 Prostate Cancer
  5. 4.2.5 Leukemia
3. 4.3 Healthcare, BY Treatment Modality (USD Billion)
  1. 4.3.1 Targeted Therapy
  2. 4.3.2 Immunotherapy
  3. 4.3.3 Combination Therapy
  4. 4.3.4 Adjuvant Therapy
  5. 4.3.5 Neoadjuvant Therapy
4. 4.4 Healthcare, BY Region (USD Billion)
  1. 4.4.1 North America
    1. 4.4.1.1 US
    2. 4.4.1.2 Canada
  2. 4.4.2 Europe
    1. 4.4.2.1 Germany
    2. 4.4.2.2 UK
    3. 4.4.2.3 France
    4. 4.4.2.4 Russia
    5. 4.4.2.5 Italy
    6. 4.4.2.6 Spain
    7. 4.4.2.7 Rest of Europe
  3. 4.4.3 APAC
    1. 4.4.3.1 China
    2. 4.4.3.2 India
    3. 4.4.3.3 Japan
    4. 4.4.3.4 South Korea
    5. 4.4.3.5 Malaysia
    6. 4.4.3.6 Thailand
    7. 4.4.3.7 Indonesia
    8. 4.4.3.8 Rest of APAC
  4. 4.4.4 South America
    1. 4.4.4.1 Brazil
    2. 4.4.4.2 Mexico
    3. 4.4.4.3 Argentina
    4. 4.4.4.4 Rest of South America
  5. 4.4.5 MEA
    1. 4.4.5.1 GCC Countries
    2. 4.4.5.2 South Africa
    3. 4.4.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Amgen (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Merck & Co. (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Novartis (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Gilead Sciences (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AstraZeneca (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Pfizer (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Johnson & Johnson (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY APPLICATION
4. 6.4 US MARKET ANALYSIS BY TYPE OF CANCER
5. 6.5 US MARKET ANALYSIS BY TREATMENT MODALITY
6. 6.6 CANADA MARKET ANALYSIS BY APPLICATION
7. 6.7 CANADA MARKET ANALYSIS BY TYPE OF CANCER
8. 6.8 CANADA MARKET ANALYSIS BY TREATMENT MODALITY
9. 6.9 EUROPE MARKET ANALYSIS
10. 6.10 GERMANY MARKET ANALYSIS BY APPLICATION
11. 6.11 GERMANY MARKET ANALYSIS BY TYPE OF CANCER
12. 6.12 GERMANY MARKET ANALYSIS BY TREATMENT MODALITY
13. 6.13 UK MARKET ANALYSIS BY APPLICATION
14. 6.14 UK MARKET ANALYSIS BY TYPE OF CANCER
15. 6.15 UK MARKET ANALYSIS BY TREATMENT MODALITY
16. 6.16 FRANCE MARKET ANALYSIS BY APPLICATION
17. 6.17 FRANCE MARKET ANALYSIS BY TYPE OF CANCER
18. 6.18 FRANCE MARKET ANALYSIS BY TREATMENT MODALITY
19. 6.19 RUSSIA MARKET ANALYSIS BY APPLICATION
20. 6.20 RUSSIA MARKET ANALYSIS BY TYPE OF CANCER
21. 6.21 RUSSIA MARKET ANALYSIS BY TREATMENT MODALITY
22. 6.22 ITALY MARKET ANALYSIS BY APPLICATION
23. 6.23 ITALY MARKET ANALYSIS BY TYPE OF CANCER
24. 6.24 ITALY MARKET ANALYSIS BY TREATMENT MODALITY
25. 6.25 SPAIN MARKET ANALYSIS BY APPLICATION
26. 6.26 SPAIN MARKET ANALYSIS BY TYPE OF CANCER
27. 6.27 SPAIN MARKET ANALYSIS BY TREATMENT MODALITY
28. 6.28 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
29. 6.29 REST OF EUROPE MARKET ANALYSIS BY TYPE OF CANCER
30. 6.30 REST OF EUROPE MARKET ANALYSIS BY TREATMENT MODALITY
31. 6.31 APAC MARKET ANALYSIS
32. 6.32 CHINA MARKET ANALYSIS BY APPLICATION
33. 6.33 CHINA MARKET ANALYSIS BY TYPE OF CANCER
34. 6.34 CHINA MARKET ANALYSIS BY TREATMENT MODALITY
35. 6.35 INDIA MARKET ANALYSIS BY APPLICATION
36. 6.36 INDIA MARKET ANALYSIS BY TYPE OF CANCER
37. 6.37 INDIA MARKET ANALYSIS BY TREATMENT MODALITY
38. 6.38 JAPAN MARKET ANALYSIS BY APPLICATION
39. 6.39 JAPAN MARKET ANALYSIS BY TYPE OF CANCER
40. 6.40 JAPAN MARKET ANALYSIS BY TREATMENT MODALITY
41. 6.41 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
42. 6.42 SOUTH KOREA MARKET ANALYSIS BY TYPE OF CANCER
43. 6.43 SOUTH KOREA MARKET ANALYSIS BY TREATMENT MODALITY
44. 6.44 MALAYSIA MARKET ANALYSIS BY APPLICATION
45. 6.45 MALAYSIA MARKET ANALYSIS BY TYPE OF CANCER
46. 6.46 MALAYSIA MARKET ANALYSIS BY TREATMENT MODALITY
47. 6.47 THAILAND MARKET ANALYSIS BY APPLICATION
48. 6.48 THAILAND MARKET ANALYSIS BY TYPE OF CANCER
49. 6.49 THAILAND MARKET ANALYSIS BY TREATMENT MODALITY
50. 6.50 INDONESIA MARKET ANALYSIS BY APPLICATION
51. 6.51 INDONESIA MARKET ANALYSIS BY TYPE OF CANCER
52. 6.52 INDONESIA MARKET ANALYSIS BY TREATMENT MODALITY
53. 6.53 REST OF APAC MARKET ANALYSIS BY APPLICATION
54. 6.54 REST OF APAC MARKET ANALYSIS BY TYPE OF CANCER
55. 6.55 REST OF APAC MARKET ANALYSIS BY TREATMENT MODALITY
56. 6.56 SOUTH AMERICA MARKET ANALYSIS
57. 6.57 BRAZIL MARKET ANALYSIS BY APPLICATION
58. 6.58 BRAZIL MARKET ANALYSIS BY TYPE OF CANCER
59. 6.59 BRAZIL MARKET ANALYSIS BY TREATMENT MODALITY
60. 6.60 MEXICO MARKET ANALYSIS BY APPLICATION
61. 6.61 MEXICO MARKET ANALYSIS BY TYPE OF CANCER
62. 6.62 MEXICO MARKET ANALYSIS BY TREATMENT MODALITY
63. 6.63 ARGENTINA MARKET ANALYSIS BY APPLICATION
64. 6.64 ARGENTINA MARKET ANALYSIS BY TYPE OF CANCER
65. 6.65 ARGENTINA MARKET ANALYSIS BY TREATMENT MODALITY
66. 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
67. 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF CANCER
68. 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT MODALITY
69. 6.69 MEA MARKET ANALYSIS
70. 6.70 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
71. 6.71 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF CANCER
72. 6.72 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT MODALITY
73. 6.73 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
74. 6.74 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF CANCER
75. 6.75 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT MODALITY
76. 6.76 REST OF MEA MARKET ANALYSIS BY APPLICATION
77. 6.77 REST OF MEA MARKET ANALYSIS BY TYPE OF CANCER
78. 6.78 REST OF MEA MARKET ANALYSIS BY TREATMENT MODALITY
79. 6.79 KEY BUYING CRITERIA OF HEALTHCARE
80. 6.80 RESEARCH PROCESS OF MRFR
81. 6.81 DRO ANALYSIS OF HEALTHCARE
82. 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE
83. 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
84. 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE
85. 6.85 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
86. 6.86 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
87. 6.87 HEALTHCARE, BY TYPE OF CANCER, 2024 (% SHARE)
88. 6.88 HEALTHCARE, BY TYPE OF CANCER, 2024 TO 2035 (USD Billion)
89. 6.89 HEALTHCARE, BY TREATMENT MODALITY, 2024 (% SHARE)
90. 6.90 HEALTHCARE, BY TREATMENT MODALITY, 2024 TO 2035 (USD Billion)
91. 6.91 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.2.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.2.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.3.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.3.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.4.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.4.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.5.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.5.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.6.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.6.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.7.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.7.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.8.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.8.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.9.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.9.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.10.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.10.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.11.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.11.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.12.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.12.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.13.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.13.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.14.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.14.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.15.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.15.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.16.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.16.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.17.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.17.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.18.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.18.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.19.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.19.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.20.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.20.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.21.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.21.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.22.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.22.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.23.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.23.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.24.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.24.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.25.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.25.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.26.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.26.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.27.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.27.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.28.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.28.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.29.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.29.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.30.2 BY TYPE OF CANCER, 2025-2035 (USD Billion)
  3. 7.30.3 BY TREATMENT MODALITY, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Cancer Biological Therapy Market Segmentation

Cancer Biological Therapy Market By Application (USD Billion, 2025-2035)

Monoclonal Antibodies
Cancer Vaccines
Cytokines and Interferons
Gene Therapy
Oncolytic Virus Therapy

Cancer Biological Therapy Market By Type of Cancer (USD Billion, 2025-2035)

Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Leukemia

Cancer Biological Therapy Market By Treatment Modality (USD Billion, 2025-2035)

Targeted Therapy
Immunotherapy
Combination Therapy
Adjuvant Therapy
Neoadjuvant Therapy

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”